Pall introduces proprietary bioreactor control system
The mPath bioreactor control system is the first to be developed and delivered by a technology supplier specifically for their product line, allowing full access to bioreactor capabilities that current commercial solutions cannot provide.
Pall Corporation has introduced the mPath bioreactor control system to the biopharmaceutical market. The mPath benchtop bioreactor control system is a first-of-its-kind solution to deliver accurate measurement and control of single-use process development-scale bioprocesses. It will support the Allegro XRS 25 bioreactor, with further expansions planned for the mPath portfolio in 2017 and beyond.
“Throughout the development of the mPath bioreactor control system, our team was focused on simplifying single-use lab-scale bioprocesses with a functional, integrated user experience,” explained Loe Cameron, Director of Analytics and Controls at Pall. “The architecture makes plug-and-play connectivity a reality, while providing access to features of Pall bioreactors that other commercial control options do not allow. In addition, the mPath bioreactor control system has been designed to support characterization and optimization, and is compliant with cGMP regulations.”
An expandable control and data management system includes both bioreactor control towers and an advanced supervisory control and data acquisition (SCADA) software package. The mPath control tower is cleanroom-ready after being IP54 designed and tested, and comes with features such as six mass flow controllers (MFCs) as standard. There are three variable speed pumps for feeds, titrants and media fills, and three biocontainer hangers with integrated load cells to organize and weigh titrants, feeds and media with a minimal footprint. All of this comes at no additional cost to buyers, and there are no limits on the number of systems or users that can run the control software.
“At Pall, we remain driven to advance the biopharmaceutical industry by delivering innovative total solutions to end users,” said Martin Smith, Chief Technology Officer at Pall. “The launch of the mPath bioreactor control system represents the first in our next generation of unifying technologies for a seamless, fully controlled, and value-based user experience.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance